Combination of THC and CBD Reduces Agitation in Late-Stage Dementia
Study found THC & CBD together can reduce agitation in late-stage dementia
In a major clinical trial, scientists found that using both tetrahydrocannabinol (THC) and cannabidiol (CBD) together can greatly reduce agitation in people with late-stage dementia.
This discovery brings new hope for patients and their caregivers in finding better ways to manage this condition.
What Did the Study Show About THC and CBD?
The study was carried out at various medical centres across the United States. It included 120 people who had Alzheimer's disease or another type of dementia. These individuals were eligible for hospice care and were experiencing agitation. They were split into two groups: one group received a special mix of THC and CBD, and the other group received a placebo.
The results were shared by Dr. Jacobo Mintzer and Brigid Reynolds at the Alzheimer’s Association International Conference on July 14. The findings were very encouraging, as almost 90% of those who received the treatment showed a major improvement in their agitation after 12 weeks.
Why Is Agitation a Problem for Dementia Patients?
Agitation is a frequent symptom in late-stage dementia and can appear as restlessness, aggression, or emotional upset. The usual treatments, such as morphine and Valium, often have unwanted side effects and may not work well. This study highlights the need for safer and more effective solutions to control agitation.
How Was the Study Carried Out?
The study, known as the LiBBY trial (Life’s end Benefits of cannaBidiol and tetrahYdrocannabinol), used a placebo-controlled method to ensure the results were unbiased. Participants, who were on average 80 years old, took either the THC/CBD mixture or a placebo, without knowing which one they had. Scientists measured agitation using a 29-item survey called the Cohen-Mansfield Agitation Inventory.
What Were the Effects of the THC/CBD Treatment?
Within just two weeks, those taking the THC and CBD combination showed a 6.27-point decrease in agitation compared to the placebo group.
After 12 weeks, the improvement continued, with 87.2% of the THC/CBD group experiencing reduced agitation, compared to only 23.6% in the placebo group.
The treatment was also found to be safe, as the number of side effects, such as infections and stomach problems, was similar between the two groups.
What Happens Next for the Participants?
After the study’s double-blind phase, participants were given the option to continue using the THC/CBD treatment for another 12 weeks.
Those who switched to the active drug continued to show reduced agitation, proving the drug’s benefits over the full 24-week period.
What Can Families Expect from This Study?
Laura, a caregiver whose mother took part in the trial, shared her hope about future treatment options. She noticed that her mother showed signs of happiness and connection during visits, indicating positive changes.
What Should Consumers Know About THC and CBD Products?
Although the study's results are encouraging, researchers warn that not all commercially available THC and CBD products are the same as the one used in the trial.
The medication tested was specially made and is different from what is available in stores.
More From Soft Secrets:
Microdosing Cannabis May Help Slow Alzheimer's Decline: New Study
L
Liz Filmer
